Ifosfamide/Paclitaxel/Cisplatin Highly Effective for Recurrent Testicular Cancer
According to results recently published in the Journal of Clinical Oncology, the chemotherapy combination of ifosfamide (Ifex®), paclitaxel (Taxol®), and cisplatin (Platinol®) appears highly effective for treatment of patients with recurrent testicular cancer.
Cancer of the testicles is the most common cancer in men 15 to 34 years old. The testicles are part of the male reproductive system and are located inside the scrotum (a loose sac of skin that lies directly under the penis). Sperm and male hormones are produced in the testicles.
Testicular cancers were among the first types of cancers to be cured by radiation or chemotherapy. Currently, most patients with testicular cancer are cured. However, a small portion of patients experience a cancer recurrence following initial therapy. Researchers continue to evaluate new chemotherapy combinations and novel therapeutic approaches for the treatment of patients with recurrent testicular cancer.
Researchers from Memorial Sloan-Kettering Cancer Center and Cornell University recently conducted a clinical trial to evaluate the chemotherapy combination of ifosfamide, paclitaxel, and cisplatin in the treatment of recurrent testicular cancer. This trial included 46 patients who had received initial treatment including cisplatin-based chemotherapy and had subsequently experienced a recurrence of their cancer.
The chemotherapy combination used on trial achieved impressive outcomes in this group of patients:
- 70% of patients achieved a complete disappearance of detectable cancer.
- Progression-free survival at two years was 65%.
Patients who did not experience a recurrence within at least two years following initial therapy had better outcomes than those who experienced a recurrence within two years of initial therapy.
The researchers concluded that the chemotherapy combination consisting of ifosfamide, paclitaxel, and cisplatin is a highly effective treatment regimen for patients with recurrent testicular cancer. Patients with recurrent testicular cancer may wish to speak with their physician regarding their individual risks and benefits of this treatment combination or the participation in a clinical trial evaluating novel therapeutic approaches. Two sources of information regarding ongoing clinical trials include the National Cancer Institute (www.cancer.gov) and www.cancerconsultants.com.
Reference: Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of Clinical Oncology. 2005;27:6549-6555.
Copyright © 2018 CancerConnect. All Rights Reserved.